- Home
- JLL vs SNN Comparison
JLL vs SNN Comparison
Compare JLL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- SNN
- Stock Information
- Founded
- JLL 1997
- SNN 1856
- Country
- JLL United States
- SNN United Kingdom
- Employees
- JLL N/A
- SNN N/A
- Industry
- JLL Real Estate
- SNN Industrial Specialties
- Sector
- JLL Finance
- SNN Health Care
- Exchange
- JLL Nasdaq
- SNN Nasdaq
- Market Cap
- JLL 14.1B
- SNN 15.2B
- IPO Year
- JLL 1997
- SNN 1999
- Fundamental
- Price
- JLL $299.07
- SNN $33.22
- Analyst Decision
- JLL Buy
- SNN Hold
- Analyst Count
- JLL 8
- SNN 4
- Target Price
- JLL $338.29
- SNN $33.50
- AVG Volume (30 Days)
- JLL 330.9K
- SNN 669.8K
- Earning Date
- JLL 11-05-2025
- SNN 10-30-2025
- Dividend Yield
- JLL N/A
- SNN 2.21%
- EPS Growth
- JLL 31.91
- SNN 59.91
- EPS
- JLL 13.05
- SNN 0.56
- Revenue
- JLL $25,317,800,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- JLL $12.21
- SNN $7.85
- Revenue Next Year
- JLL $8.43
- SNN $5.43
- P/E Ratio
- JLL $22.08
- SNN $28.79
- Revenue Growth
- JLL 12.51
- SNN 5.35
- 52 Week Low
- JLL $194.36
- SNN $23.69
- 52 Week High
- JLL $322.37
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- JLL 47.84
- SNN 33.56
- Support Level
- JLL $274.71
- SNN $31.83
- Resistance Level
- JLL $307.56
- SNN $37.06
- Average True Range (ATR)
- JLL 8.61
- SNN 0.54
- MACD
- JLL -1.84
- SNN -0.33
- Stochastic Oscillator
- JLL 50.71
- SNN 24.43
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.